Seegene has launched the Global Million Clinical Study to collect real-world data on the clinical utility of syndromic PCR testing for infectious diseases, aiming to inform future global diagnostic standards.
The insurer will provide coverage for the multi-analyte test starting July 2026, following new data showing parity with mass spectrometry.
A new NIH-funded study finds that elevated circular RNAs in blood may predict Alzheimer’s symptoms years in advance, outperforming current blood tests in forecasting disease progression.
A highly sensitive blood test for KRAS mutations detected pancreatic cancer recurrence in more patients than standard methods, according to Northwestern Medicine research.
The automated assay identifies latent infections in routine laboratory settings with results available in less than 24 hours.
The expanded commercialization agreement aims to increase availability of the GlycoKnow Ovarian laboratory-developed test through Aranscia's clinical workflow and technology platforms.
As autoimmune and allergy test volumes rise, labs are prioritizing workflow standardization and structured testing pathways to ensure reliable results, according to Santhosh Nair, president of immunodiagnostics at Thermo Fisher Scientific.
The assay measures lipoprotein(a) levels in molar units to improve cardiovascular risk assessment and standardization across laboratories.
Presentations will evaluate the performance of the company's pTau217 and pTau181 assays while also highlighting phase 3 clinical research for the investigational therapy trontinemab for Alzheimer's disease.
A two-year real-world study of Renalytix’s FDA-approved KidneyIntelX.dkd test showed improved kidney function and targeted treatment in 2,470 patients with type 2 diabetes.
Elevated donor-derived cell-free DNA levels are linked to higher kidney transplant failure risk, suggesting earlier detection of allograft injury before loss of kidney function.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
The BD BACTEC FXI Culture System reduces detection time for bloodstream infections by approximately three hours compared to previous models.